Prognostic value of CA125, HE4, ROMA, and CPH-I in advanced epithelial ovarian cancer
Two blood biomarker combinations—ROMA and CPH-I—predicted which ovarian cancer patients would benefit from surgery, informing treatment planning.
In 97 advanced EOC patients, ROMA and CPH-I demonstrated the highest AUC for predicting suboptimal cytoreductive surgery outcomes (AUC ~0.80), while all four biomarkers independently predicted platinum sensitivity and recurrence. These findings support preoperative biomarker panels for surgical and treatment planning in advanced ovarian cancer.
What the study was
- Study design
- Retrospective cohort study with ROC and Kaplan-Meier analysis
- Population
- 261 patients total (80 benign, 84 early EOC, 97 advanced EOC); Tengzhou Central People's Hospital, 2018–2024
- Sample size
- 261
- Category
- Diagnostics
- Maturity
- Exploratory
- Journal
- BMC Cancer
Why it surfaced
Clinically useful data on established biomarkers in advanced EOC; ROMA/CPH-I performance for cytoreduction prediction is actionable at ~AUC 0.80. Single-centre, retrospective; modest n=97 advanced EOC.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.